Monitor for any conversion of the 13G to a 13D, which would signal activist intent. The large warrant overhang (14M+ warrants) could create future dilution risk if exercised.
PMVP drugs
PMVP drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK AT ENTRY AT T+1- T+0 · Nov 17 $1.22entry
- T+1 · 4d ago 0.00%α +0.31% · $1.22
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 24d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tang Capital Management and related entities filed an amended Schedule 13G disclosing a 9.99% beneficial ownership stake in PMV Pharmaceuticals as of September 30, 2026, consisting of 7,572,727 shares of common stock (including 287,642 shares issuable upon warrant exercise) plus pre-funded warrants and additional warrants. The filing updates a prior 13G and reflects the group's passive investment status following the company's August 2026 public offering.
Key Financial Metrics
Key Facts
- Tang Capital Management and Kevin Tang beneficially own 7,572,727 shares of PMVP common stock (9.99% of outstanding).
- Stake includes 7,285,085 common shares and 287,642 shares issuable upon exercise of warrants.
- Group also holds 11,000,000 pre-funded warrants and 14,040,000 warrants to purchase common stock.
- Filing is an amendment to a prior Schedule 13G, maintaining passive investor status.
- Date of event: September 30, 2026; filing date: November 16, 2026.
Financial Impact
9.99% beneficial ownership stake valued at approximately $7.6M based on 7,572,727 shares; no transaction disclosed.
Risk Factors
- Passive filing; no indication of activist intent at this time.
- Substantial warrant overhang (14,040,000 warrants plus pre-funded warrants) may pressure stock if exercised.
- No change in stake from prior filing; no new buying or selling disclosed.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001214659-26-014414 |
| Document: 0001214659-26-014414-index.html | 0001214659-26-014414 |
| Document: 0001214659-26-014414.txt | 0001214659-26-014414 |
Track record
14 reports on PMVP
3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +29.46% at T+20 after the Aug 31, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 20, 20261d ago Press Release Bullish 7/10 Entry $1.20 Now $0.8760 −27.00% settles Dec 21
- Nov 16, 20265d ago SC 13G/A Neutral 3/10 Viewing Entry $1.22 Now $0.8760 −28.20% settles Dec 16
- Nov 10, 202611d ago 8-K Neutral 5/10 Entry $1.22 Now $0.8760 −28.20% settles Dec 9
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $1.78 to $1.31 Now $0.8760 −50.79% ▼ −26.40% −23.94% vs SPY
- Aug 31, 202611w ago Press Release Bearish 8/10 Entry $1.29 to $1.67 Now $0.8760 +32.09% ▼ −29.46% −29.14% vs SPY
- Aug 31, 202611w ago 8-K Bullish 7/10 Entry $1.29 to $1.67 Now $0.8760 −32.09% ▲ +29.46% +29.14% vs SPY
- Aug 31, 202611w ago Press Release Bearish 6/10 Entry $1.29 to $1.67 Now $0.8760 +32.09% ▼ −29.46% −29.14% vs SPY
- Aug 31, 202611w ago Press Release Bullish 8/10 Entry $1.29 to $1.67 Now $0.8760 −32.09% ▲ +29.46% +29.14% vs SPY
- Aug 14, 202614w ago 8-K Neutral 5/10 No price data
- Aug 14, 202614w ago Press Release Bullish 6/10 Entry $1.26 to $1.46 Now $0.8760 −30.48% ▲ +15.87% +17.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers